Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

Claus F. Vogelmeier,1,21 Gerard J. Criner,2,21 Fernando J. Martinez,3,21 Antonio Anzueto,6 Peter J. Barnes,5 Jean Bourbeau,6 Bartolome R. Celli,7 Rongchang Chen,8 Marc Decramer,9 Leonardo M. Fabbri,10 Peter Frith,11 David M.G. Halpin,12 M. Victorina López Varela,13 Masaharu Nishimura,14 Nicolas Roche,15 Roberto Rodríguez-Roisin,16 Don D. Sin,17 Dave Singh,18 Robert Stockley,19 Jørgen Vestbo,18 Jadwiga A. Wedzicha,5 and Alvar Agusti20

Affiliations: 1University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany. 2Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 3New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA. 4University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX, USA. 5National Heart and Lung Institute, Imperial College, London, UK. 6McGill University Health Centre, McGill University, Montreal, Canada. 7Brigham and Women’s Hospital, Boston, MA, USA. 8State Key Lab for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 9University of Leuven, Leuven, Belgium. 10University of Modena and Reggio Emilia, Modena, Italy. 11Flinders University Faculty of Medicine, Bedford Park, Australia. 12Royal Devon and Exeter Hospital, Exeter, UK. 13Universidad de la República, Hospital Maciel, Montevideo, Uruguay. 14Hokkaido University School of Medicine, Sapporo, Japan. 15Hôpital Cochin (APHP), University Paris Descartes, Paris, France. 16Thorax Institute, Hospital Clinic Universitat de Barcelona, Barcelona, Spain. 17St Paul’s Hospital, University of British Columbia, Vancouver, Canada. 18University of Manchester, Manchester, UK. 19University Hospital, Birmingham, UK. 20Hospital Clínic, Universitat de Barcelona, Ciberes, Barcelona, Spain. 21These authors contributed equally to the manuscript.

Correspondence: Claus F. Vogelmeier, Dept of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Baldingerstraße, 35043 Marburg, Germany. E-mail: claus.vogelmeier@med.uni-marburg.de

@ERSpublications
Read the executive summary of the new @GOLD_COPD 2017 report in the European Respiratory Journal http://ow.ly/XxfD308BDfc


ABSTRACT This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.

This article has been amended according to the erratum published in the June 2017 issue of the European Respiratory Journal.

This article has supplementary material available from erj.ersjournals.com

Received: Jan 30 2017 | Accepted: Jan 30 2017

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©2017 the American Thoracic Society. Published with permission from the American Thoracic Society. Design and branding are copyright ©ERS 2017.
Introduction
This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report is based on peer-reviewed publications to October 2016.

Levels of evidence are assigned to evidence-based recommendations where appropriate. Categories used to grade the levels of evidence are provided in table S1 in the supplementary material.

Definition and factors that influence chronic obstructive pulmonary disease development and progression

Key points
- Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
- Dyspnoea, cough and/or sputum production are the most frequent symptoms; symptoms are commonly under-reported by patients.
- Tobacco smoking is the main risk exposure for COPD, but environmental exposures like biomass fuel exposure and air pollution may contribute. Besides exposures, host factors (genetic abnormalities, abnormal lung development and accelerated aging) predispose individuals to develop COPD.
- COPD may be punctuated by acute worsening of respiratory symptoms, called exacerbations.
- In most patients, COPD is associated with significant concomitant chronic diseases, which increase morbidity and mortality.

Definition and pathogenesis
COPD is a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

The chronic airflow limitation that characterises COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person. Chronic inflammation causes structural changes, small airways narrowing and destruction of lung parenchyma. A loss of small airways may contribute to airflow limitation and mucociliary dysfunction, a characteristic feature of the disease.

Chronic respiratory symptoms may precede the development of airflow limitation and be associated with acute respiratory events [1]. Chronic respiratory symptoms may exist in individuals with normal spirometry [1, 2] and a significant number of smokers without airflow limitation have structural evidence of lung disease manifested by the presence of emphysema, airway wall thickening and gas trapping [1, 2].

Factors that influence disease development and progression
Although cigarette smoking is the most well studied COPD risk factor, epidemiologic studies demonstrate that non-smokers may also develop chronic airflow limitation [3]. Compared to smokers with COPD, never smokers with chronic airflow limitation have fewer symptoms, milder disease and a lower burden of systemic inflammation [4]. Never smokers with chronic airflow limitation do not have an increased risk of lung cancer, or cardiovascular comorbidities; however, they have an increased risk of pneumonia and mortality from respiratory failure [4].

Processes occurring during gestation, birth, and exposures during childhood and adolescence affect lung growth [5, 6]. Reduced maximal attained lung function (as measured by spirometry) may identify individuals at increased risk for COPD [2, 7]. Factors in early life termed “childhood disadvantage factors” are as important as heavy smoking in predicting lung function in adult life [8]. An examination of three different longitudinal cohorts found that approximately 50% of patients developed COPD owing to an accelerated decline in forced expiratory volume in 1 s (FEV1); the other 50% developed COPD owing to abnormal lung growth and development.

This document is an executive summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report. The documents were peer reviewed by GOLD before submission to the European Respiratory Journal, the American Journal of Respiratory and Critical Care Medicine, Archivos de Bronconeumología and Respirology for joint publication.
Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of decline in FEV1, and a greater COPD mortality rate than non-smokers [9]. Other types of tobacco (e.g., pipe, cigar, water pipe) [10–12] and marijuana [13] are also risk factors for COPD. Passive exposure to cigarette smoke, also known as environmental tobacco smoke (ETS), may also contribute to respiratory symptoms and COPD [14] by increasing the lung’s total burden of inhaled particles and gases. Smoking during pregnancy may pose a risk for the fetus by affecting in utero lung growth and development, and possibly priming the immune system [15].

Occupational exposures, including organic and inorganic dusts, chemical agents and fumes, are under-appreciated risk factors for COPD development [16, 17].

Wood, animal dung, crop residues, and coal, typically burned in open fires or poorly functioning stoves, may lead to indoor air pollution [18]. Indoor pollution from biomass cooking and heating, in poorly ventilated dwellings, is a risk for COPD [19–21].

Asthma may be a risk for the development of chronic airflow limitation and COPD [22]. Airway hyper-responsiveness can exist without a clinical diagnosis of asthma and is an independent predictor of COPD and respiratory mortality in population studies [23, 24], and may indicate a risk for excessive lung function decline in mild COPD [25].

A history of severe childhood respiratory infection is associated with reduced lung function and increased respiratory symptoms in adulthood [26]. HIV infection accelerates the onset of smoking-related emphysema and COPD [27]; tuberculosis has also been identified as a risk for COPD as well as a potential comorbidity [28–30].

**Diagnosis and initial assessment**

**Key points**

- COPD should be considered in any patient with dyspnoea, chronic cough or sputum production, and/or a history of exposure to risk factors.
- Spirometry is required to make the diagnosis; a post-bronchodilator FEV1/FVC <0.70 confirms the presence of persistent airflow limitation.
- The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death) to guide therapy.
- Concomitant chronic diseases occur frequently in COPD patients and should be treated because they can independently affect mortality and hospitalisations.

**Diagnosis**

COPD should be considered in any patient with dyspnoea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease (figure 1 and table 1). Spirometry is required to make the diagnosis in this clinical context [31]; a post-bronchodilator FEV1/FVC <0.70 confirms the presence of persistent airflow limitation and identifies the presence of COPD in patients with appropriate symptoms and predisposing risks.

**Symptoms**

Chronic and progressive dyspnoea is the most characteristic symptom of COPD.

**Dyspnoea**

Dyspnoea is a major cause of disability and anxiety in COPD [32]. The terms used to describe dyspnoea vary individually and culturally [33].
Cough
Chronic cough is often the first symptom of COPD and frequently discounted by the patient as a consequence of smoking and/or environmental exposures.

Sputum production
Regular sputum production \(\geq 3\) months in 2 consecutive years is the classical definition of chronic bronchitis [34]; an arbitrary definition that does not reflect the range of sputum production reported in COPD. Patients producing large volumes of sputum may have underlying bronchiectasis.

Wheezing and chest tightness
Wheezing and chest tightness may vary between days, and throughout a single day.

Additional features in severe disease
Fatigue, weight loss and anorexia are common in patients with more severe forms of COPD [35, 36].

Medical history
A detailed medical history of any patient who is known, or suspected, to have COPD should include:

- Exposure to risk factors, such as smoking and occupational or environmental exposures.
- Past medical history, including asthma, allergy, sinusitis, or nasal polyps; respiratory infections in childhood; other chronic respiratory and non-respiratory diseases.
- Family history of COPD or other chronic respiratory diseases.
- Pattern of symptom development: age of onset, type of symptom, more frequent or prolonged “winter colds,” and social restriction.
- History of exacerbations or previous hospitalisations for a respiratory disorder.
- Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, and malignancies.
- Impact of disease on patient’s life, including limitation of activity, missed work and economic impact, and feelings of depression or anxiety.
- Social and family support available to the patient.
- Possibilities for reducing risk factors, especially smoking cessation.

Physical examination
Although important for general health, a physical examination is rarely diagnostic in COPD. Physical signs of airflow limitation/hyperinflation are usually not identifiable until significantly impaired lung function is present [37, 38].

Spirometry
Spirometry is the most reproducible and objective measurement of airflow limitation. It is a noninvasive and readily available test. Good quality spirometry is possible in any healthcare setting; all healthcare workers who care for COPD patients should have access to spirometry.
A post-bronchodilator fixed ratio of FEV1/FVC <0.70 is the spirometric criterion for airflow limitation. This criterion is simple and independent of reference values and has been used in numerous clinical trials. However, it may result in more frequent diagnosis of COPD in the elderly [39, 40], especially in mild disease, compared to a cut-off based on the lower limit of normal (LLN) values for FEV1/FVC. Several limitations occur with using LLN as the diagnostic criterion for spirometric obstruction: 1) LLN values are dependent on the choice of reference equations that use post-bronchodilator FEV1, 2) there are no longitudinal studies that validate using the LLN, and 3) studies using LLN in populations where smoking is not the major cause of COPD are lacking.

Normal spirometry may be defined by a new approach from the Global Lung Initiative (GLI) [41, 42]. Using GLI equations, z scores were calculated for FEV1, FVC, and FEV1/FVC and compared to fixed ratio data. The findings suggest that among adults with GLI-defined normal spirometry, the use of a fixed ratio may misclassify individuals as having respiratory impairment. These findings await additional study in other cohorts.

The risk of misdiagnosis and over-treatment using the fixed ratio as a diagnostic criterion is limited since spirometry is only one parameter used to establish the clinical diagnosis of COPD. GOLD favours using the fixed ratio over LLN since diagnostic simplicity and consistency are crucial for the busy clinician.

Assessing the degree of reversibility of airflow limitation (e.g., measuring FEV1 before and after bronchodilator or corticosteroids) to make therapeutic decisions is not recommended [43] since it does not aid the diagnosis of COPD, differentiate COPD from asthma, or predict the long-term response to treatment [44].

In asymptomatic individuals without exposures to tobacco or other noxious stimuli, screening spirometry is not indicated. However, in those with symptoms and/or risk factors (e.g., >20 pack-years of smoking or recurrent chest infections), the diagnostic yield for COPD is relatively high and spirometry should be considered [45, 46]. GOLD advocates active case finding [45, 47] i.e., performing spirometry in patients with symptoms and/or risk factors, but not routine screening spirometry in asymptomatic individuals without COPD risk factors.

**Assessment**

The goals of COPD assessment to guide therapy are 1) to determine the level of airflow limitation; 2) to define its impact on the patient’s health status and; 3) to identify the risk of future events (such as exacerbations, hospital admissions or death).

To achieve these goals, COPD assessment must consider separately the following aspects of the disease:

- Presence and severity of the spirometric abnormality
- Current nature and magnitude of symptoms
- History/future risk of exacerbations
- Presence of comorbidities

**Classification of severity of airflow limitation**

Spirometry should be performed after administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimise variability.

The role of spirometry for the diagnosis, assessment and follow-up of COPD is summarised in table 2.

**Assessment of symptoms**

COPD was previously viewed as a disease largely characterised by breathlessness. A simple measure of breathlessness such as the Modified British Medical Research Council (mMRC) Questionnaire [48] was considered adequate for assessment of symptoms [49–51]. However, COPD impacts patients well beyond dyspnoea [52]. For this reason, a comprehensive assessment of symptoms is recommended. The most
comprehensive disease-specific health status questionnaires include the Chronic Respiratory Questionnaire (CRQ) [53] and St. George’s Respiratory Questionnaire (SGRQ) [54]. These are too complex to use in clinical practice, but shorter measures e.g., the COPD Assessment Test (CAT) are suitable.

Choice of thresholds
SGRQ scores <25 are uncommon in COPD patients [55] and scores ≥25 are very uncommon in healthy persons [56, 57]. The equivalent cut-off point for the CAT is 10 [58]. A mMRC threshold of ≥2 is used to separate “less breathlessness” from “more breathlessness”.

Assessment of exacerbation risk
The best predictor of frequent exacerbations (defined as ≥2 exacerbations per year) is a history of earlier treated events [59]. Hospitalisation for a COPD exacerbation has a poor prognosis and an increased risk of death [60].

Blood eosinophil count
Post-hoc analysis of two clinical trials in COPD patients with an exacerbation history showed that higher blood eosinophil counts may predict increased exacerbation rates in patients treated with long acting beta agonists (LABA) (without inhaled corticosteroid, ICS) [61, 62]. The treatment effect of ICS/LABA versus LABA on exacerbations was greater in patients with higher blood eosinophil counts. These findings suggest that blood eosinophil counts are 1) a biomarker of exacerbation risk in patients with a history of exacerbations and 2) can predict the effects of ICS on exacerbation prevention. Prospective trials are required to validate the use of blood eosinophil counts to predict ICS effects, to determine a cut-off threshold for blood eosinophils that predicts exacerbation risk, and to clarify blood eosinophil cut-off values that could be used in clinical practice.

Assessment of concomitant chronic diseases (comorbidities)
Patients with COPD often have important concomitant chronic illnesses as COPD represents an important component of multimorbidity particularly in the elderly [60, 63–65].

Revised combined COPD assessment
The “ABCD” assessment tool of the 2011 GOLD Report was a major step forward from the simple spirometric grading system of earlier GOLD Reports because it incorporated patient-reported outcomes and highlighted the importance of exacerbation prevention in COPD management. However, there were important limitations. ABCD assessment performed no better than spirometric grades for mortality prediction or other important health outcomes [66–68]. Moreover, group “D” outcomes were modified by two parameters: lung function and/or exacerbation history, which caused confusion [69]. To address these concerns, the 2017 GOLD Report provides a refinement of the ABCD assessment that separates spirometric grades from ABCD groupings. For some therapy recommendations, especially pharmacologic treatments, ABCD groups are derived exclusively from patient symptoms and their exacerbation history. However, spirometry, in conjunction with patient symptoms and exacerbation history, remains vital for the diagnosis, prognostication and consideration of other important therapeutic approaches, especially nonpharmacological therapies. This new approach to assessment is illustrated in figure 2.

In the refined assessment scheme, patients should undergo spirometry to determine the severity of airflow limitation (i.e., spirometric grade). They should also undergo assessment of either dyspnoea using mMRC or symptoms using CAT. Finally, their history of exacerbations (including prior hospitalisations) should be recorded.

The number provides information regarding severity of airflow limitation (spirometric grades 1–4) while the letter (groups A–D) provides information regarding symptom burden and risk of exacerbation. FEV1 is a very important parameter at the population level in the prediction of important clinical outcomes such as mortality and hospitalisations or prompting consideration for nonpharmacologic therapies such as lung reduction or lung transplantation. However, at the individual patient level, FEV1 loses precision and thus cannot be used alone to determine all therapeutic options. Furthermore, in some circumstances, such as during hospitalisation or urgent presentation to the clinic or emergency room, the ability to assess patients based on symptoms and exacerbation history, independent of the spirometric value, allows clinicians to initiate a treatment plan based on the revised ABCD scheme. This approach acknowledges the limitations of FEV1 in making treatment decisions for individualised patient care and highlights the importance of patient symptoms and exacerbation risks in guiding therapies in COPD. The separation of airflow limitation from clinical parameters makes it clearer what is being evaluated and ranked. This should facilitate more precise treatment recommendations based on parameters that are driving the patient’s symptoms at any given time.
Example

Consider two patients – both patients with FEV1 <30% of predicted and CAT scores of 18, and one with no exacerbations in the past year, and the other with three exacerbations in the past year. Both would have been labelled GOLD D in the prior classification scheme. However, with the new proposed scheme, the subject with 3 exacerbations in the past year would be labelled GOLD grade 4, group D. Individual decisions on pharmacotherapeutic approaches would use the recommendations based on the ABCD assessment to treat the patient’s major problem at this time, i.e., persistent exacerbations. The other patient, who has had no exacerbations, would be classified as GOLD grade 4, group B. In such patients – besides pharmacotherapy and rehabilitation – lung reduction, lung transplantation or bullectomy may be important therapeutic considerations given their symptom burden and level of spirometric limitation.

α1-antitrypsin deficiency

The World Health Organization recommends that all patients with a diagnosis of COPD be screened once for α1-antitrypsin deficiency [70]. A low concentration (<20% normal) is suggestive of homozygous deficiency. Family members should be screened and together with the patient referred to specialist centres for advice and management.

Additional investigations

In order to rule out other concomitant disease contributing to respiratory symptoms, or in cases where patients do not respond to the treatment plan as expected, additional testing may be required. Thoracic imaging (chest X-ray, chest computed tomography (CT)), assessment of lung volumes and/or diffusion capacity, oximetry and arterial blood gas measurement, and exercise testing and assessment of physical activity should be considered.

Composite scores

The BODE (body mass index, obstruction, dyspnoea, and exercise) method gives a composite score that is a better predictor of subsequent survival than any single component [71]. Simpler alternatives that do not include exercise testing need validation to confirm suitability for routine clinical use [72, 73].

Differential diagnoses

In some patients, features of asthma and COPD may coexist. The terms “asthma–COPD overlap syndrome” or “asthma–COPD overlap” acknowledge the overlap of these two common disorders causing chronic airflow limitation rather than designating it a distinct syndrome. Most other potential differential diagnoses are easier to distinguish from COPD.

Other considerations

Some patients without evidence of airflow limitation have evidence of structural lung disease on chest imaging (emphysema, gas trapping, airway wall thickening). Such patients may report exacerbations of
respiratory symptoms or even require treatment with respiratory medications on a chronic basis. Whether these patients have acute or chronic bronchitis, a persistent form of asthma or an earlier presentation of what will become COPD as it is currently defined, is unclear and requires further study.

Prevention and maintenance therapy

Key points

- Smoking cessation is key. Pharmacotherapy and nicotine replacement increase long-term smoking abstinence rates.
- The effectiveness and safety of e-cigarettes as a smoking cessation aid is uncertain.
- Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance.
- Each pharmacologic treatment regimen should be individualised and guided by the severity of symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the patient’s response, preference and ability to use various drug delivery devices.
- Inhaler technique needs to be assessed regularly.
- Influenza and pneumococcal vaccinations decrease the incidence of lower respiratory tract infections.
- Pulmonary rehabilitation improves symptoms, quality of life, and physical and emotional participation in everyday activities.
- In patients with severe resting chronic hypoxaemia, long-term oxygen therapy improves survival.
- In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely, however, individual patient factors should be considered.
- In patients with severe chronic hypercapnia and a history of hospitalisation for acute respiratory failure, long-term non-invasive ventilation (NIV) may decrease mortality and prevent re-hospitalisation.
- In select patients with advanced emphysema refractory to optimised medical care, surgical or bronchoscopic interventional treatments may be beneficial.
- Palliative approaches are effective in controlling symptoms in advanced COPD.

Smoking cessation

Smoking cessation influences the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long-term quit success rates of up to 25% can be achieved [74].

Nicotine replacement products

Nicotine replacement therapy increases long-term smoking abstinence rates [75–77] and is more effective than placebo. E-cigarettes are increasingly used as a form of nicotine replacement therapy, although their efficacy remains controversial [78–82].

Pharmacologic products

Varenicline [83], bupropion [84], and nortriptyline [85] increase long-term quit rates [85], but should be used as part of an interventional programme rather than as a sole intervention.

Smoking cessation programmes

A five-step programme for intervention [75] provides a framework to guide healthcare providers to help patients stop smoking [75, 77, 86]. Counselling delivered by health professionals significantly increases quit rates over self-initiated strategies [87]. The combination of pharmacotherapy and behavioural support increases smoking cessation rates [88].

Vaccinations

Influenza vaccine and pneumococcal vaccines

Influenza vaccination reduces serious illness [89], death [90–93], the risk of ischaemic heart disease [94] and the total number of exacerbations [90]. Vaccines containing either killed or live inactivated viruses are recommended [95] as they are more effective in elderly patients with COPD [96].

The pneumococcal vaccinations, the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), are recommended for all patients ≥65 years of age (table S2).

Pharmacologic therapy for stable COPD

Overview of medications

Pharmacologic therapy for COPD reduces symptoms, the frequency and severity of exacerbations, and improves exercise tolerance and health status. No existing medication modifies the long-term decline in
lung function [97–101]. The classes of medications used to treat COPD are shown in table S3. The choice within each class depends on the availability and cost of medication and favourable clinical response balanced against side-effects. Each treatment regimen needs to be individualised as the relationship between severity of symptoms, airflow limitation, and severity of exacerbations varies between patients.

**Bronchodilators**

Bronchodilators increase FEV1, reduce dynamic hyperinflation, at rest and during exercise [102, 103], and improve exercise performance. Bronchodilator medications are usually given on a regular basis to prevent or reduce symptoms. Toxicity is dose-related.

**β₂-agonists**

β₂-agonists, including short-acting (SABA) and long-acting (LABA) agents, relax airway smooth muscle. Stimulation of β₂-adrenergic receptors can produce resting sinus tachycardia and precipitate cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor occurs in some patients treated with higher doses of β₂-agonists.

**Antimuscarinic drugs**

Ipratropium, a short-acting muscarinic antagonist, provides small benefits over short-acting β₂-agonist in terms of lung function, health status and requirement for oral steroids [104]. Long-acting muscarinic antagonist (LAMA) treatment improves symptoms and health status [105, 106], improves the effectiveness of pulmonary rehabilitation [107, 108] and reduces exacerbations and related hospitalisations [107]. Clinical trials have shown a greater effect on exacerbation rates for LAMA treatment (tiotropium) versus LABA treatment [109, 110]. An unexpected small increase in cardiovascular events was reported in COPD patients regularly treated with ipratropium bromide [111, 112]. A large trial reported no difference in mortality, cardiovascular morbidity or exacerbation rates when using tiotropium as a dry-powder inhaler compared to a mist delivered by the Respimat inhaler [113].

**Methylxanthines**

Theophylline exerts a modest bronchodilator effect in stable COPD [114], and improves FEV1 and breathlessness when added to salmeterol [115, 116]. There is limited and contradictory evidence regarding the effect of low-dose theophylline on exacerbation rates [114, 119]. Toxicity is dose-related, which is a problem as most of the benefit occurs when near-toxic doses are given [116, 121].

**Combination bronchodilator therapy**

Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator (table 3) [120]. There are numerous combinations of a LABA and LAMA in a single inhaler available (table S3). These combinations improve lung function compared to placebo [120] and

<table>
<thead>
<tr>
<th>TABLE 3 Bronchodilators in stable chronic obstructive pulmonary disease (COPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhaled bronchodilators in COPD are central to symptom management and commonly given on a regular basis to prevent or reduce symptoms [evidence A]</td>
</tr>
<tr>
<td>Regular and as-needed use of SABA or SAMA improves FEV1 and symptoms [evidence A]</td>
</tr>
<tr>
<td>Combinations of SABA and SAMA are superior compared to either medication alone in improving FEV1 and symptoms [evidence A]</td>
</tr>
<tr>
<td>LABAs and LAMAs significantly improve lung function, dyspnoea, health status, and reduce exacerbation rates [evidence A]</td>
</tr>
<tr>
<td>LAMAs have a greater effect on exacerbation reduction compared with LABAs [evidence A] and decrease hospitalisations [evidence B]</td>
</tr>
<tr>
<td>Combination treatment with a LABA and LAMA increases FEV1 and reduces symptoms compared to monotherapy [evidence A]</td>
</tr>
<tr>
<td>Combination treatment with a LABA and LAMA reduces exacerbations compared to monotherapy [evidence B] or ICS/LABA [evidence B]</td>
</tr>
<tr>
<td>Tiotropium improves the effectiveness of pulmonary rehabilitation in increasing exercise performance [evidence B]</td>
</tr>
<tr>
<td>Theophylline exerts a small bronchodilator effect in stable COPD [evidence A] that is associated with modest symptomatic benefits [evidence B]</td>
</tr>
</tbody>
</table>

have a greater impact on patient reported outcomes compared to monotherapies [121–124]. LABA/LAMA improves symptoms and health status in COPD patients [125], is more effective than long-acting bronchodilator monotherapy for preventing exacerbations [126], and decreases exacerbations to a greater extent than ICS/LABA combination [127].

**Anti-inflammatory agents**

Exacerbations represent the main clinically relevant end-point used for the efficacy assessment of anti-inflammatory drugs (table 4).

**Inhaled corticosteroids**

In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function and health status, and reducing exacerbations [128, 129]. However, survival is not affected by combination therapy [130, 131].

ICS use has a higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia [132]. Patients at higher risk of pneumonia include those who currently smoke, are aged ≥55 years, or have a history of prior exacerbations or pneumonia, a body mass index (BMI) <25 kg·m⁻², a poor MRC dyspnoea grade and/or severe airflow limitation [133].

Results from randomised controlled trials (RCTs) have yielded variable results regarding the risk of decreased bone density and fractures with ICS treatment [99, 134–137]. Observational studies suggest that ICS treatment could be associated with increased risks of diabetes/poor control of diabetes [138], cataracts [139], and mycobacterial infection [140] including tuberculosis [141, 142].

**ICS withdrawal**

Withdrawal studies provide equivocal results regarding the consequences of withdrawal on lung function, symptoms and exacerbations [143–147].

<table>
<thead>
<tr>
<th>TABLE 4 Anti-inflammatory therapy in stable chronic obstructive pulmonary disease (COPD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICS</strong></td>
</tr>
<tr>
<td>An ICS combined with a LABA is more effective than the individual components in improving lung function and health status and reducing exacerbations in patients with exacerbations and moderate to very severe COPD [evidence A]</td>
</tr>
<tr>
<td>Regular treatment with ICS increases the risk of pneumonia especially in those with severe disease [evidence A]</td>
</tr>
<tr>
<td>Triple inhaled therapy of ICS/LAMA/LABA improves lung function, symptoms and health status [evidence A] and reduces exacerbations [evidence B] compared to ICS/LABA or LAMA monotherapy</td>
</tr>
<tr>
<td><strong>Oral glucocorticoids</strong></td>
</tr>
<tr>
<td>Long-term use of oral glucocorticoids has numerous side-effects [evidence A] with no evidence of benefits [evidence C]</td>
</tr>
<tr>
<td><strong>PDE4 inhibitors</strong></td>
</tr>
<tr>
<td>In patients with chronic bronchitis, severe to very severe COPD and a history of exacerbations A PDE4 inhibitor improves lung function and reduces moderate and severe exacerbations [evidence A]</td>
</tr>
<tr>
<td>A PDE4 inhibitor improves lung function and decreases exacerbations in patients who are on fixed-dose LABA/ICS combinations [evidence B]</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
</tr>
<tr>
<td>Long-term azithromycin and erythromycin therapy reduces exacerbations over 1 year [evidence A]</td>
</tr>
<tr>
<td>Treatment with azithromycin is associated with an increased incidence of bacterial resistance [evidence A] and hearing test impairment [evidence B]</td>
</tr>
<tr>
<td><strong>Mucolytics/antioxidants</strong></td>
</tr>
<tr>
<td>Regular use of NAC and carbocysteine reduces the risk of exacerbations in select populations [evidence B]</td>
</tr>
<tr>
<td><strong>Other anti-inflammatory agents</strong></td>
</tr>
<tr>
<td>Simvastatin does not prevent exacerbations in COPD patients at increased risk of exacerbations and without indications for statin therapy [evidence A]; however, observational studies suggest that statins may have positive effects on some outcomes in patients with COPD who receive them for cardiovascular and metabolic indications [evidence C]</td>
</tr>
<tr>
<td>Leukotriene modifiers have not been tested adequately in COPD patients</td>
</tr>
</tbody>
</table>

ICS: inhaled corticosteroid; LABA: long-acting β₂-agonist; LAMA: long-acting muscarinic antagonist; PDE: phosphodiesterase; N-acetylcysteine.
**Triple inhaled therapy**
Combination of LABA plus LAMA plus ICS (triple therapy) may improve lung function and patient reported outcomes [148–151] and reduce exacerbation risk [149, 152–154]. However, one RCT failed to demonstrate any benefit of adding an ICS to LABA plus LAMA on exacerbations [155]. More evidence is needed to compare the benefits of triple therapy (LABA/LAMA/ICS) to LABA/LAMA.

**Oral glucocorticoids**
Oral glucocorticoids have no role in the chronic daily treatment of COPD because of a lack of benefit balanced against a high rate of systemic complications.

**Phosphodiesterase-4 inhibitors**
Roflumilast reduces moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations [156]. Phosphodiesterase-4 (PDE4) inhibitors have more adverse effects than inhaled medications for COPD [157]. The most frequent are diarrhoea, nausea, reduced appetite, weight loss, abdominal pain, sleep disturbance, and headache. Roflumilast should be avoided in underweight patients and used with caution in patients with depression.

**Antibiotics**
Azithromycin (250 mg·day$^{-1}$ or 500 mg three times per week) or erythromycin (500 mg two times per day) for 1 year reduces the risk of exacerbations in patients prone to exacerbations [158–160]. Azithromycin use showed a reduced exacerbation rate in former smokers only and was associated with an increased incidence of bacterial resistance and impaired hearing tests [160]. Pulse moxifloxacin therapy in patients with chronic bronchitis and frequent exacerbations does not reduce exacerbation rate [161].

**Mucolytic (mucokinetics, mucoregulators) and antioxidant agents \((N\text{-}acetylcysteine, \text{carbocysteine})\)**
Regular treatment with mucolytics such as carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status in patients not receiving ICS [162, 163].

**Other drugs with anti-inflammatory potential**
Although RCTs suggest that immunoregulators decrease the severity and frequency of exacerbations [164, 165], the long-term effects of this therapy are unknown. Nedocromil and leukotriene modifiers have not been adequately tested in COPD [166]. There was no evidence of benefit, and some evidence of harm, following treatment with an anti-tumour necrosis factor-\(\alpha\) antibody (infliximab) in moderate to severe COPD [167]. Simvastatin did not prevent exacerbations in patients with COPD who had no metabolic or cardiovascular indication for statin treatment [168]. An association between statin use and improved outcomes has been reported in observational studies of patients with COPD who received them for cardiovascular and metabolic indications [169]. There is no evidence that vitamin D supplementation reduces exacerbations in unselected patients [170].

**Issues related to inhaled delivery**
Observational studies have identified a significant relationship between poor inhaler use and symptom control in COPD [171]. Determinants of poor inhaler technique include older age, use of multiple devices, and lack of previous education on inhaler technique [172]. Education improves inhalation technique in some but not all patients [172], especially when the “teach-back” approach is implemented [173].

Other pharmacologic treatments for COPD are summarised in table S4.

**\(\alpha_1\)-Antitrypsin augmentation therapy**
Observational studies suggest a reduction in spirometric progression in \(\alpha_1\)-antitrypsin deficiency patients treated with augmentation therapy versus non-treated patients [174]. Studies using sensitive parameters of emphysema progression determined by CT scans provide evidence for an effect on preserving lung tissue compared to placebo [175–177].

**Antitussives**
The role of antitussives in patients with COPD is inconclusive [178].

**Vasodilators**
Available studies report worsening gas exchange [179] with little improvement in exercise capacity or health status in COPD patients [180, 181].

https://doi.org/10.1183/13993003.00214-2017
Rehabilitation, education, and self-management

Pulmonary rehabilitation
Pulmonary rehabilitation is a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies (e.g., exercise training, education, self-management interventions aimed at behaviour changes to improve physical and psychological condition and promote adherence to health-enhancing behaviours in patients with COPD) [182]. The benefits of pulmonary rehabilitation are considerable (table S5). Pulmonary rehabilitation can reduce readmissions and mortality in patients following a recent exacerbation (<4 weeks from prior hospitalisation) [183]. Initiating pulmonary rehabilitation before hospital discharge, however, may compromise survival [184].

Pulmonary rehabilitation represents integrated patient management that includes a range of healthcare professionals [185] and sites, including hospital inpatient and outpatient settings and/or the patient’s home [182].

Education, self-management, and integrative care

Education
Smoking cessation, correct use of inhaler devices, early recognition of exacerbation, decision making, when to seek help, surgical interventions, and the consideration of advance directives, are examples of educational topics.

Self-management
Self-management interventions that use written negotiated action plans for worsening symptoms may lead to less respiratory-related hospitalisation and all cause hospitalisations and improved health status [186]. The health benefits of COPD self-management programmes may be negated by increased mortality [187, 188]. Generalisation to real life remains difficult.

Integrated care programmes
Integrated care programmes improve several clinical outcomes, although not mortality [189]. However, a large multi-centre study within an existing well-organised system of care did not confirm this [190]. Delivering integrated interventions by telemedicine provided no significant benefit [191].

Supportive, palliative, end-of-life, and hospice care

Symptom control and palliative care
The goal of palliative care is to prevent and relieve suffering, and to improve quality of life for patients and their families, regardless of the stage of disease or the need for other therapies [192]. Palliation efforts should be focussed on the relief of dyspnoea, pain, anxiety, depression, fatigue, and poor nutrition.

End-of-life and hospice care
End-of-life care discussions should include patients and their families [193]. Advance care planning can reduce anxiety for patients and their families; ensure that care is consistent with their wishes and avoid unnecessary, unwanted and costly invasive therapies [194, 195] (table S6) the approach to palliation, end-of-life and hospice care

Other treatments

Oxygen therapy and ventilatory support

Oxygen therapy
The long-term administration of oxygen (>15 h per day) to patients with chronic respiratory failure increases survival in patients with severe resting hypoxaemia [196]. Long-term oxygen therapy does not lengthen time to death or first hospitalisation or provide sustained benefit for any of the measured outcomes in patients with stable COPD and resting or exercise-induced moderate arterial oxygen desaturation [197].

Ventilatory support
Whether to use noninvasive positive pressure ventilation (NPPV) chronically at home to treat patients with acute on chronic respiratory failure following hospitalisation remains undetermined. Retrospective studies have provided inconclusive data [198, 199]. RCTs have yielded conflicting data on the use of home NPPV on survival and re-hospitalisation in chronic hypercapnic COPD [200–203]. In patients with both COPD and obstructive sleep apnoea (OSA) continuous positive airway pressure improves survival and avoids hospitalisation (table S7) [204].

https://doi.org/10.1183/13993003.00214-2017
**Interventional therapy**

**Surgical interventions**

**Lung volume reduction surgery**

A RCT confirmed that COPD patients with upper-lobe emphysema and low post-rehabilitation exercise capacity experienced improved survival when treated with lung volume reduction surgery (LVRS) compared to medical treatment [205]. In patients with high post-pulmonary rehabilitation exercise capacity, no difference in survival was noted after LVRS, although health status and exercise capacity improved. LVRS has been demonstrated to result in higher mortality than medical management in severe emphysema patients with an FEV1 ≤ 20% predicted and either homogeneous emphysema in high-resolution computed tomography (HRCT) or a diffusing capacity of the lung for carbon monoxide of ≤ 20% of predicted [206].

**Bullectomy**

In selected patients with relatively preserved underlying lung, bullectomy is associated with decreased dyspnoea, improved lung function and exercise tolerance [207].

**Lung transplantation**

In selected patients lung transplantation has been shown to improve health status and functional capacity but not to prolong survival [207–209]. Bilateral lung transplantation has been reported to have longer survival than single lung transplantation in COPD patients, especially those <60 years of age [210].

**Bronchoscopic interventions to reduce hyperinflation in severe emphysema**

Less invasive bronchoscopic approaches to lung reduction have been developed [211]. Prospective studies have shown that the use of bronchial stents is not effective [212] while use of lung sealant caused significant morbidity and mortality [213]. A RCT of endobronchial valve placement showed statistically significant improvements in FEV1 and 6-min walk distance compared to control therapy at 6 months post intervention [214] but the magnitude of the observed improvements was not clinically meaningful. Subsequently, efficacy of the same endobronchial valve has been studied in patients with heterogeneous [215], or heterogeneous and homogenous emphysema [216] with mixed outcomes.

Two multi-centre trials have examined nitinol coils implanted into the lung compared to usual care reported increases in 6-min walk distance with coil treatment compared to control and smaller improvements in FEV1 and quality of life measured by St George’s Respiratory Questionnaire [217, 218].

Additional data are needed to define the optimal patient population to receive a specific bronchoscopic lung volume technique and to compare the long-term durability of improvements in functional or physiological performance to LVRS relative to side effects [218].

**Key points for interventional therapy in stable COPD** are summarised in table S8.

**Management of stable COPD**

**Key points**

- The management strategy for stable COPD should be based on individualised symptom assessment and future risk of exacerbations.
- All individuals who smoke should be supported to quit.
- The main treatment goals are reduction of symptoms and future risk of exacerbations.
- Management strategies are not limited to pharmacologic treatments, and should be complemented by appropriate nonpharmacologic interventions.

Effective COPD management should be based on an individualised assessment to reduce both current symptoms and future risks of exacerbations (figure S1).

We propose personalisation of initiating and escalating/de-escalating treatments based on the level of symptoms and an individual’s risk of exacerbations. The basis for these recommendations is partially based on evidence generated in RCTs. These recommendations are intended to support clinician decision-making.


Identify and reduce exposure to risk factors

Cigarette smoking is the most commonly encountered and easily identifiable risk factor for COPD; smoking cessation should be continually encouraged for current smokers. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to indoor and outdoor air pollutants, should be addressed.

Treatment of stable COPD

Pharmacologic treatment

Pharmacologic therapies can reduce symptoms, the risk and severity of exacerbations, and improve health status and exercise tolerance. The choice within each class depends on the availability of medication and the patient’s response and preference (tables 5–7).

Pharmacologic treatment algorithms

A proposed model for the initiation, and then subsequent escalation and/or de-escalation of pharmacologic management according to the individualised assessment of symptoms and exacerbation risk is shown in figure 3. In past GOLD Reports, recommendations were only given for initial therapy. However, many COPD patients are already on treatment and return with persistent symptoms after initial therapy, or less commonly with resolution of some symptoms that may subsequently require less therapy. Therefore, we now suggest escalation and de-escalation strategies. The recommendations are based on available efficacy and safety data. We acknowledge that treatment escalation has not been systematically tested; trials of de-escalation are also limited and only include ICS. There is a lack of direct evidence supporting the therapeutic recommendations for patients in groups C and D. These recommendations will be re-evaluated as additional data become available.

Group A

All Group A patients should be offered a bronchodilator to reduce breathlessness. This can be either a short or a long-acting bronchodilator based on the individual patient’s preference. The bronchodilator should be continued if symptomatic benefit is noted.

TABLE 5 Key points for the use of bronchodilators

| LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnoea (evidence A) |
| Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnoea on one bronchodilator treatment should be escalated to two (evidence A). |
| Inhaled bronchodilators are recommended over oral bronchodilators (evidence A) |
| Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable (evidence B) |

LABA: long-acting \( \beta_2 \)-agonist; LAMA: long-acting muscarinic antagonist.

TABLE 6 Key points for the use of anti-inflammatory agents

| Long-term monotherapy with ICS is not recommended (evidence A) |
| Long-term treatment with ICS may be considered in association with LABAs for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators (evidence A) |
| Long-term therapy with oral corticosteroids is not recommended (evidence A) |
| In patients with exacerbations despite LABA/ICS or LABA/LAMA/ICS, chronic bronchitis and severe to very severe airflow obstruction, the addition of a PDE4 inhibitor can be considered (evidence B) |
| In former smokers with exacerbations despite appropriate therapy, macrolides can be considered (evidence B) |
| Statin therapy is not recommended for prevention of exacerbations (evidence A) |
| Antioxidant mucolytics are recommended only in selected patients (evidence A) |

ICS: inhaled corticosteroid; LABA: long-acting \( \beta_2 \)-agonist; LAMA: long-acting muscarinic antagonist; PDE: phosphodiesterase.
Group B
Initial therapy should be a long acting bronchodilator. Long-acting bronchodilators are superior to short-acting bronchodilators taken intermittently [104, 219]. There is no evidence to recommend one class of long-acting bronchodilators over another for symptom relief; the choice should depend on individual patient response.

For patients with persistent breathlessness on monotherapy [220] the use of two bronchodilators is recommended. For patients with severe breathlessness, initial therapy with two bronchodilators may be considered.

Group C
Initial therapy should be a single long-acting bronchodilator. In two head-to-head comparisons [110, 111] the LAMA tested superior to the LABA regarding exacerbation prevention, therefore we recommend initiating a LAMA in this group.

Patients with persistent exacerbations may benefit from adding a second long-acting bronchodilator (LABA/LAMA), or using LABA/ICS. As ICS increases the risk for developing pneumonia, our primary choice is LABA/LAMA.

Group D
We recommend initiating a LABA/LAMA combination because:

- In studies with patient reported outcomes as the primary endpoint, LABA/LAMA combinations showed superior results compared to a single bronchodilator.
- LABA/LAMA combination was superior to LABA/ICS combination in preventing exacerbations and improving other patient reported outcomes in Group D patients.
- Group D patients are at higher risk for pneumonia when receiving ICS treatment [111, 133].

If a single bronchodilator is initially chosen, a LAMA is preferred for exacerbation prevention based on comparison to LABAs.

LABA/ICS may be the first choice for initial therapy in some patients. These patients may have a history and/or findings suggestive of asthma–COPD overlap and/or high blood eosinophil counts.

In patients who develop additional exacerbations on LABA/LAMA therapy we suggest two alternative pathways:

- Escalation to LABA/LAMA/ICS.
- Switch to LABA/ICS. If LABA/ICS therapy does not positively impact exacerbations/symptoms, a LAMA can be added.

If patients treated with LABA/LAMA/ICS still have exacerbations the following options may be considered:

- Add roflumilast. This may be considered in patients with an FEV1 <50% predicted and chronic bronchitis [221], particularly if they experienced at least one hospitalisation for an exacerbation in the previous year [222].
- Add a macrolide in former smokers. The possibility of developing resistant organisms should be factored into the decision making.
- Stopping ICS. This recommendation is supported by data that shows an elevated risk of adverse effects (including pneumonia) and no significant harm from ICS withdrawal.

Nonpharmacologic treatment
Education and self-management
An individual patient’s evaluation and risk assessment (e.g., exacerbations, patient’s needs, preferences, and personal goals) should aid the design of personalised self-management.

TABLE 7 Key points for the use of other pharmacologic treatments

| Patients with severe hereditary α1-antitrypsin deficiency and established emphysema may be candidates for α1-antitrypsin augmentation therapy (evidence B) |
| Antifusives cannot be recommended (evidence C) |
| Drugs approved for primary pulmonary hypertension are not recommended for patients with pulmonary hypertension secondary to COPD (evidence B) |
| Low-dose long acting oral and parenteral opioids may be considered for treating dyspnoea in COPD patients with severe disease (evidence B) |

COPD: chronic obstructive pulmonary disease.
Pulmonary rehabilitation programmes

Patients with high symptom burden and risk of exacerbations (groups B, C and D), should take part in a full rehabilitation programme that considers the individual’s characteristics and comorbidities [182, 187, 223].

Exercise training

A combination of constant load or interval training with strength training provides better outcomes than either method alone [224]. Adding strength training to aerobic training is effective in improving strength, but does not improve health status or exercise tolerance [225]. Upper extremity exercise training improves arm strength and endurance and improves capacity for upper extremity activities [226].

Self-management education

An educational programme should include smoking cessation; basic information about COPD; aspects of medical treatment (respiratory medications and inhalation devices); strategies to minimise dyspnoea; advice about when to seek help; and possibly a discussion of advance directives and end-of-life issues.

End-of-life and palliative care

Patients should be informed that should they become critically ill, they or their family members may need to decide whether a course of intensive care is likely to achieve their personal goals of care. Simple, structured conversations about these possible scenarios should be discussed while patients are in their stable state [227].

Nutritional support

For malnourished patients with COPD nutritional supplementation is recommended.
Vaccination

Influenza vaccination is recommended for all patients with COPD. The pneumococcal vaccinations PCV13 and PPSV23 are recommended for all patients >65 years of age. PPSV23 is also recommended for younger COPD patients with significant comorbid conditions including chronic heart or lung disease [228].

Oxygen therapy

Long-term oxygen therapy is indicated for stable patients who have:

- arterial oxygen tension ($P_{aO_2}$) at or below 7.3 kPa (55 mmHg) or arterial oxygen saturation ($S_{aO_2}$) at or below 88%, with or without hypercapnia confirmed twice over a three-week period; or
- $P_{aO_2}$ between 7.3 kPa (55 mmHg) and 8.0 kPa (60 mmHg), or $S_{aO_2}$ of 88%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive cardiac failure, or polycythaemia (haematocrit >55%).

Ventilatory support

NIV is occasionally used in patients with stable very severe COPD. NIV may be considered in a selected group of patients, particularly those with pronounced daytime hypercapnia and recent hospitalisation, although contradictory evidence exists regarding its effectiveness [229]. In patients with both COPD and OSA continuous positive airway pressure is indicated [204].

Interventional bronchoscopy and surgery

- In selected patients with heterogenous or homogenous emphysema and significant hyperinflation refractory to optimised medical care, surgical or bronchoscopic modes of lung volume reduction (e.g., endobronchial one-way valves or lung coils) may be considered [230].
- In selected patients with a large bulla, surgical bullectomy may be considered.
- In selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.

Choosing bronchoscopic lung reduction or LVRS to treat hyperinflation in a patient with emphysema depends on a number of factors that include: the extent and pattern of emphysema identified on HRCT; the presence of interlobar collateral ventilation measured by fissure integrity on HRCT or physiological assessment (endoscopic balloon occlusion and flow assessment); local proficiency in the performance of the procedures; and patient and provider preferences. An algorithm depicting the various interventions based on radiological and physiological features is shown in figure 4.

Criteria for referral for lung transplantation include COPD with progressive disease, not a candidate for endoscopic or surgical lung volume reduction, BODE index of 5–6, carbon dioxide tension >50 mmHg or advanced COPD.

---

**Figure 4:** Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Overview of various therapies used to treat patients with COPD and emphysema worldwide. Note that not all therapies are approved for clinical care in all countries. Additionally, the effects of bronchoscopic lung volume reduction (BLVR) or survival on other long-term outcomes or comparison to lung volume reduction surgery (LVRS) are unknown. EBV: endobronchial valve; LVRC: lung volume reduction coil. " at some but not all centres.
6.6 kPa and/or $P_aO_2 < 60$ mmHg or 8 kPa, and FEV1 <25% predicted [231]. Recommended criteria for listing include one of the following: BODE index >7, FEV1 <15–20% predicted, three or more severe exacerbations during the preceding year, one severe exacerbation with acute hypercapnic respiratory failure, or moderate to severe pulmonary hypertension [231, 232].

Key points for the use of nonpharmacologic treatments are summarised in table S9.

**Monitoring and follow-up**

Routine follow-up of COPD patients is essential. Symptoms, exacerbations and objective measures of airflow limitation should be monitored to determine when to modify management and to identify any complications and/or comorbidities that may develop. In order to adjust therapy appropriately as the disease progresses, each follow-up visit should include a discussion of the current therapeutic regimen. Symptoms that indicate worsening or development of another comorbid condition should be evaluated and treated.

**Management of exacerbations**

### Key points

- An exacerbation of COPD is an acute worsening of respiratory symptoms that results in additional therapy.
- Exacerbations can be precipitated by several factors. The most common causes are respiratory tract infections.
- The goal for treatment of exacerbations is to minimise the negative impact of the current exacerbation and to prevent subsequent events.
- Short-acting inhaled $\beta_2$-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation.
- Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge.
- Systemic corticosteroids improve lung function (FEV1), oxygenation and shorten recovery time and hospitalisation duration.
- Antibiotics, when indicated, shorten recovery time, and reduce the risk of early relapse or treatment failure, and hospitalisation duration.
- Methylxanthines are not recommended owing to side-effects.
- Non-invasive mechanical ventilation should be the first mode of ventilation used to treat acute respiratory failure.
- Following an exacerbation, appropriate measures for exacerbation prevention should be initiated.

Exacerbations are important events in the management of COPD because they negatively impact health status, rates of hospitalisation and readmission, and disease progression [237, 238]. COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. Increased dyspnoea is the key symptom of an exacerbation. Other symptoms include increased sputum purulence and volume, together with increased cough and wheeze [239]. As comorbidities are common in COPD patients, exacerbations must be differentiated from acute coronary syndrome, worsening congestive heart failure, pulmonary embolism and pneumonia.

COPD exacerbations are classified as:

- Mild (treated with short-acting bronchodilators (SABDs) only),
- Moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or
- Severe (patient requires hospitalisation or visits the emergency room). Severe exacerbations may be associated with acute respiratory failure.

Exacerbations are mainly triggered by respiratory viral infections although bacterial infections and environmental factors may also initiate and/or amplify these events [236].

Exacerbations can be associated with increased sputum production and, if purulent, increased bacteria may be found in the sputum [235, 237, 238]. Some evidence supports the concept that eosinophils are increased in the airways, lung, and blood in a significant proportion of patients with COPD. Exacerbations associated with an increase in sputum or blood eosinophils may be more responsive to systemic steroids [239] although more prospective data are needed [239].

Symptoms usually last between 7 to 10 days during an exacerbation, but some events may last longer. At 8 weeks, 20% of patients have not recovered to their pre-exacerbation state [240]. COPD exacerbations increase susceptibility to additional events [59, 245].
COPD patients susceptible to frequent exacerbations (defined as ≥2 exacerbations per year) have worse health status and morbidity than patients with less frequent exacerbations [234]. Other factors associated with an increased risk of acute exacerbations and/or severity of exacerbations include an increase in the ratio of the pulmonary artery to aorta cross sectional dimension (i.e., ratio >1) [242], a greater percentage of emphysema or airway wall thickness [243] measured by chest CT imaging and the presence of chronic bronchitis [244, 248].

**Treatment options**

**Treatment setting**

The goals of exacerbation treatment are to minimise the negative impact of the current exacerbation, and to prevent the development of subsequent events [246]. Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than 80% of exacerbations are managed on an outpatient basis with bronchodilators, corticosteroids, and antibiotics [59, 247, 248].

The indications for hospitalisation during a COPD exacerbation are shown in table S10. When patients with a COPD exacerbation come to the emergency department, they should be given supplemental oxygen and assessed to determine whether the exacerbation is life-threatening and requires consideration for NIV and intensive care unit (ICU) or respiratory unit hospitalisation.

Long-term prognosis following hospitalisation for COPD exacerbation is poor; the 5-year mortality rate is about 50% [249]. Factors associated with poor outcomes include older age, lower BMI, comorbidities (e.g., cardiovascular disease or lung cancer), previous hospitalisations for COPD exacerbations, clinical severity of the index exacerbation, and need for long-term oxygen therapy at discharge [250, 251]. Patients with a higher prevalence and severity of respiratory symptoms, poorer quality of life, worse lung function, lower exercise capacity, lower lung density and thickened bronchial walls on CT scan are at increased mortality risk following an acute exacerbation [252].

Key points for the management of all exacerbations are given in table 8.

**Pharmacologic treatment**

The most commonly used classes of medications for COPD exacerbations are bronchodilators, corticosteroids, and antibiotics.

**Bronchodilators**

Short-acting inhaled β₂-agonists, with or without short-acting anticholinergics, are the initial bronchodilators recommended for acute treatment of exacerbations [253, 254]. There are no significant differences in FEV₁ when using metered dose inhalers (with or without a spacer device) or nebulisers to deliver the agent [255], although the latter may be an easier delivery method for sicker patients. Intravenous methylxanthines are not recommended owing to side-effects [256, 257].

**Glucocorticoids**

Systemic glucocorticoids in COPD exacerbations shorten recovery time and improve FEV₁. They also improve oxygenation [258–261], the risk of early relapse, treatment failure [262], and the length of hospitalisation [258, 260, 263]. A dose of 40 mg prednisone per day for 5 days is recommended [264].

**TABLE 8 Key points for the management of exacerbations**

| Short-acting inhaled β₂-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation (evidence C) |
| Systemic corticosteroids improve lung function (FEV₁), oxygenation and shorten recovery time and hospitalisation duration. Duration of therapy should not be more than 5–7 days (evidence A). |
| Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalisation duration. Duration of therapy should be 5–7 days (evidence B). |
| Methylxanthines are not recommended due to increased side effect profiles (evidence B) |
| NIV should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalisation duration and improves survival (evidence A) |

FEV₁: forced expiratory volume in 1 s; NIV: non-invasive ventilation; COPD: chronic obstructive pulmonary disease.
Therapy with oral prednisolone is equally effective to intravenous administration [265]. Glucocorticoids may be less efficacious to treat exacerbations in patients with lower blood eosinophil levels [59, 239, 266].

Antibiotics
The use of antibiotics in exacerbations remains controversial [267–269]. Evidence supports the use of antibiotics in patients with exacerbations and increased sputum purulence [268, 269]. One review reported that antibiotics reduce the risk of short-term mortality by 77%, treatment failure by 53% and sputum purulence by 44% [270]. Procalcitonin-guided antibiotic treatment may reduce antibiotic exposure and side-effects with the same clinical efficacy [271, 272]. A study in patients with exacerbations requiring mechanical ventilation (invasive or non-invasive) reported increased mortality and a higher incidence of secondary nosocomial pneumonia when antibiotics were not given [273]. Antibiotics should be given to patients with acute exacerbations who have three cardinal symptoms: increase in dyspnoea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive) [235, 236]. The recommended length of antibiotic therapy is 5–7 days [274].

Antibiotic choice should be based on the local bacterial resistance pattern. Usual initial empirical treatment is an aminopenicillin with clavulanic acid, a macrolide, or a tetracycline. In patients with frequent exacerbations, severe airflow limitation [275, 276], and/or exacerbations requiring mechanical ventilation [277], cultures from sputum or other materials from the lung should be performed to identify the presence of resistant pathogens. Administration route depends on the patient’s ability to eat and the pharmacokinetics of the antibiotic.

Respiratory support
Oxygen therapy
Supplemental oxygen should be titrated to improve hypoxaemia with a target saturation of 88–92% [278]. Once oxygen is started, blood gases should be checked to ensure satisfactory oxygenation without carbon dioxide retention and/or worsening acidosis.

Ventilatory support
Some patients require admission to the ICU. Admission of patients with severe exacerbations to intermediate or special respiratory care units may be appropriate if adequate personnel skills and equipment exist to manage acute respiratory failure.

Noninvasive mechanical ventilation
NIV is preferred over invasive ventilation as the initial mode of ventilation to treat acute respiratory failure in patients hospitalised for acute exacerbations of COPD. NIV has been studied in RCTs showing a success rate of 80–85% [279–283]. Mortality and intubation rates are reduced by NIV [279, 284–286].

Invasive mechanical ventilation
The indication for initiating invasive mechanical ventilation during an exacerbation includes failure of an initial trial of NIV [287]. In patients who fail NIV as initial therapy and receive invasive ventilation as subsequent rescue therapy, morbidity, hospital length of stay and mortality are greater [282].

Hospital discharge and follow-up
Lack of spirometric assessment and arterial blood gas analysis have been associated with re-hospitalisation and mortality [288]. Mortality relates to patient age, the presence of acidic respiratory failure, the need for ventilatory support and comorbidities including anxiety and depression [289].

The introduction of care bundles at hospital discharge to include education, optimisation of medication, supervision and correction of inhaler technique, assessment and optimal management of comorbidities, early rehabilitation, telemonitoring and continued patient contact have been investigated [290]. There is insufficient data that they influence readmission rates, short-term mortality [288, 289, 291, 292] or cost-effectiveness [289].

Early follow-up (<30 days) following discharge should be undertaken when possible and has been related to less exacerbation-related readmissions [184, 293]. Early follow-up permits a careful review of discharge therapy and an opportunity to make changes in therapy. Patients not attending early follow-up have increased 90-day mortality.

Additional follow-up at 3 months is recommended to ensure return to a stable state and review of patient’s symptoms, lung function (by spirometry), and when possible the assessment of prognosis using multiple
scoring systems such as BODE [293, 294]. An assessment of the presence and management of comorbidities should also be undertaken (table S11) [295].

Prevention of exacerbations
After an acute exacerbation, measures for prevention of further exacerbations should be initiated (table S12).

COPD and comorbidities

Key points
- COPD often coexists with other diseases (comorbidities) that may significantly impact patient outcomes.
- The presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD.
- When COPD is part of a multi-morbidity care plan, attention should be directed to ensure simplicity of treatment and minimise polypharmacy.

COPD often coexists with other diseases (comorbidities) that may have a significant impact on prognosis [63, 296–302]. Some of these arise independently of COPD whereas others may be causally related, either with shared risk factors, or by one disease increasing the risk or compounding the severity of the other [303]. Management of the COPD patient must include identification and treatment of its comorbidities; the most common in COPD are outlined below.

Cardiovascular disease

Heart failure
The prevalence of systolic or diastolic heart failure in COPD patients ranges from 20% to 70% [304]. Unrecognised heart failure may mimic or accompany acute exacerbations of COPD; 40% of COPD patients that are mechanically ventilated because of hypercapnic respiratory failure have evidence of left ventricular dysfunction [305, 306]. Treatment with β₁-blockers improves survival in chronic heart failure and is recommended. Selective β₁-blockers should be used [307].

Ischaemic heart disease
There is an increased risk of myocardial damage in patients with concomitant ischaemic heart disease who have an acute exacerbation of COPD. Patients who demonstrate abnormal cardiac troponins are at an increased risk of adverse outcomes including short-term (30-day) and long-term mortality [308].

Arrhythmias
Cardiac arrhythmias are common in COPD and vice versa. Atrial fibrillation is frequent and directly associated with FEV₁. Bronchodilators have been previously described as potentially pro-arrhythmic agents [309, 310]; however, evidence suggests an overall acceptable safety profile for LABA [311] and anticholinergic drugs (and ICS) [101, 113, 248, 312–316].

Peripheral vascular disease
In a large cohort of patients with COPD of all degrees of severity, 8.8% were diagnosed with peripheral artery disease (PAD), which was higher than the prevalence in non-COPD controls (1.8%) [317]. COPD patients with PAD reported a worse functional capacity and worse health status compared to those without PAD.

Hypertension
Hypertension is likely to be the most frequently occurring comorbidity in COPD and may have implications for prognosis [303, 318].

Osteoporosis
Osteoporosis is often associated with emphysema [319, 320], decreased BMI [321] and low fat-free mass [322]. Low bone mineral density and fractures are common in COPD patients even after adjustment for steroid use, age, pack-years of smoking, current smoking and exacerbations [323, 324]. An association between ICS and fractures has been found in pharmaco-epidemiological studies. Systemic corticosteroids significantly increase the risk of osteoporosis.
Anxiety and depression
Anxiety and depression are both associated with a poor prognosis [325, 326].

Lung cancer
The association between emphysema and lung cancer is stronger than between airflow limitation and lung cancer [327–329]. Increased age and greater smoking history further increase risk [330]. Two studies of low-dose chest computed tomography (LDCT) screening report improved survival in subjects aged 55–74 years, current smokers or those who quit within the previous 15 years, with a smoking history of at least 30 pack-years [331, 332]. LDCT is now recommended in the USA for patients meeting these demographics; however, this is not a worldwide practice.

Metabolic syndrome and diabetes
Metabolic syndrome and diabetes are more frequent in COPD and the latter is likely to affect prognosis [297]. The prevalence of metabolic syndrome has been estimated to be >30% [332].

Gastro-oesophageal reflux
Gastro-oesophageal reflux is an independent risk factor for exacerbations and is associated with worse health status [59, 334, 335].

Bronchiectasis
Bronchiectasis is associated with longer exacerbations [336] and increased mortality [295].

Obstructive sleep apnoea
Patients with “overlap syndrome” (COPD and OSA) have a worse prognosis compared with COPD or OSA. Apnoeic events in patients with OSA and COPD have more profound hypoxaemia and more cardiac arrhythmias [337] and are more likely to develop daytime pulmonary hypertension [338, 339] than patients with just OSA or COPD alone.

References

https://doi.org/10.1183/13993003.00214-2017


Medical Research Council Committee on the Aetiology of Chronic Bronchitis. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965; 1: 775–779.


Hansen JE, Porszasz J. Counterpoint: Is an increase in FEV1 and/or FVC predictive of mortality in COPD. Chest 2004; 126: 1431–1440.


https://doi.org/10.1183/13993003.00214-2017

23


